Answers are grounded in this paper and cite their sources.
Automated screening develops bacteriophage cocktails in clinical trials, highlighting a new approach to combat infections.
We present the high-throughput automated screening techniques that are being used to develop bacteriophage-based therapeutic products currently under investigation in human clinical trials to combat urinary tract infections 1 . By integrating modern liquid handling robotics, standardized phenotypic assays, and computer vision-based enumeration, we established a platform capable of reproducibly screening large collections of phages against clinically derived bacterial strain panels. This approach enabled systematic assessment of phage-bacteria interactions at scale, facilitating the identification and optimization of phage cocktails with broad in vitro activity. Although bacteriophage therapy has long been investigated as a strategy for treating bacterial infections, few frameworks exist for developing phage combinations in a reproducible and scalable manner. The methods outlined here address this gap and aim to support the broader development of therapeutic assets available to combat antibiotic resistance.
No takes yet. Share an insight, caveat, or question.
Penke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: